Sunesis Pharmaceuticals Company Profile (NASDAQ:SNSS)

About Sunesis Pharmaceuticals (NASDAQ:SNSS)

Sunesis Pharmaceuticals logoSunesis Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML). Vosaroxin is an anticancer quinolone derivative (AQD). The Company's other kinase inhibitor pipeline include TAK-580, SNS-062 and SNS-229. TAK-580 is an oral, investigative drug selective for pan-Raf kinase inhibition, in patients with relapsed or refractory solid tumors. SNS-062 is a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK). The Company has completed the pre-clinical studies for SNS-062. SNS-229 and SNS-510 are two PDK1 inhibitors. PDK1 is a kinase and mediator of Phosphoinositide 3-kinase/AKT (PI3K/AKT) signaling, which is a pathway involved in cell growth, differentiation, survival and migration.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:SNSS
  • CUSIP: 86732860
  • Web: www.sunesis.com
Capitalization:
  • Market Cap: $66.31 million
  • Outstanding Shares: 21,460,000
Average Prices:
  • 50 Day Moving Avg: $3.41
  • 200 Day Moving Avg: $3.86
  • 52 Week Range: $2.82 - $6.30
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.93
  • P/E Growth: -0.01
Sales & Book Value:
  • Annual Revenue: $2.57 million
  • Price / Sales: 25.80
  • Book Value: ($0.21) per share
  • Price / Book: -14.71
Profitability:
  • EBIDTA: ($36,020,000.00)
  • Net Margins: -1,623.12%
  • Return on Equity: -806.43%
  • Return on Assets: -111.92%
Debt:
  • Current Ratio: 2.39%
  • Quick Ratio: 2.39%
Misc:
  • Average Volume: 115,512 shs.
  • Beta: 1.88
  • Short Ratio: 0.95
 

Frequently Asked Questions for Sunesis Pharmaceuticals (NASDAQ:SNSS)

What is Sunesis Pharmaceuticals' stock symbol?

Sunesis Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNSS."

How were Sunesis Pharmaceuticals' earnings last quarter?

Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) posted its earnings results on Monday, May, 8th. The company reported ($0.47) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.83) by $0.36. The company had revenue of $0.67 million for the quarter, compared to analyst estimates of $1.57 million. Sunesis Pharmaceuticals had a negative return on equity of 806.43% and a negative net margin of 1,623.12%. The business's revenue was up 4.7% compared to the same quarter last year. During the same period last year, the company earned ($0.12) earnings per share. View Sunesis Pharmaceuticals' Earnings History.

Where is Sunesis Pharmaceuticals' stock going? Where will Sunesis Pharmaceuticals' stock price be in 2017?

3 brokerages have issued 1-year price objectives for Sunesis Pharmaceuticals' shares. Their predictions range from $3.00 to $3.00. On average, they expect Sunesis Pharmaceuticals' stock price to reach $3.00 in the next year. View Analyst Ratings for Sunesis Pharmaceuticals.

What are analysts saying about Sunesis Pharmaceuticals stock?

Here are some recent quotes from research analysts about Sunesis Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. " (5/11/2017)
  • 2. Cantor Fitzgerald analysts commented, "Losing Vosaroxin. SNSS has withdrawn its MAA in the EU for vosaroxin, ending the company’s chances, we believe, for marketing approval without additional clinical studies." (5/2/2017)

Who are some of Sunesis Pharmaceuticals' key competitors?

Who are Sunesis Pharmaceuticals' key executives?

Sunesis Pharmaceuticals' management team includes the folowing people:

  • Daniel N. Swisher Jr., President, Chief Executive Officer, Director
  • Adam R. Craig M.D. Ph.D., Executive Vice President - Development, Chief Medical Officer
  • James W. Young Ph.D., Non-Executive Independent Chairman of the Board
  • Stephen B. Ketchum Ph.D., Director
  • Geoffrey M. Parker, Director
  • Steve R Carchedi, Independent Director
  • Matthew K. Fust, Independent Director

Who owns Sunesis Pharmaceuticals stock?

Sunesis Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include NEA Management Company LLC (6.20%), Palo Alto Investors LLC (5.56%), Vanguard Group Inc. (2.78%), Boxer Capital LLC (2.51%), Driehaus Capital Management LLC (1.72%) and First Eagle Investment Management LLC (1.53%). Company insiders that own Sunesis Pharmaceuticals stock include Daniel N Swisher Jr, Dayton Misfeldt and Geoffrey M Parker. View Institutional Ownership Trends for Sunesis Pharmaceuticals.

Who sold Sunesis Pharmaceuticals stock? Who is selling Sunesis Pharmaceuticals stock?

Sunesis Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC and Driehaus Capital Management LLC. View Insider Buying and Selling for Sunesis Pharmaceuticals.

Who bought Sunesis Pharmaceuticals stock? Who is buying Sunesis Pharmaceuticals stock?

Sunesis Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc., TFS Capital LLC, Morgan Stanley, Neuberger Berman Group LLC, Geode Capital Management LLC and Renaissance Technologies LLC. Company insiders that have bought Sunesis Pharmaceuticals stock in the last two years include Daniel N Swisher Jr, Dayton Misfeldt and Geoffrey M Parker. View Insider Buying and Selling for Sunesis Pharmaceuticals.

How do I buy Sunesis Pharmaceuticals stock?

Shares of Sunesis Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sunesis Pharmaceuticals' stock price today?

One share of Sunesis Pharmaceuticals stock can currently be purchased for approximately $3.09.


MarketBeat Community Rating for Sunesis Pharmaceuticals (NASDAQ SNSS)
Community Ranking:  2.6 out of 5 ( )
Outperform Votes:  106 (Vote Outperform)
Underperform Votes:  100 (Vote Underperform)
Total Votes:  206
MarketBeat's community ratings are surveys of what our community members think about Sunesis Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sunesis Pharmaceuticals (NASDAQ:SNSS) (?)
Ratings Breakdown: 2 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.33)
Consensus Price Target: $3.00 (2.91% downside)

Analysts' Ratings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/2/2017Cantor FitzgeraldReiterated RatingHold$3.00HighView Rating Details
11/3/2016Cowen and CompanyReiterated RatingHoldN/AView Rating Details
7/29/2016Wells Fargo & CoUpgradeMarket Perform -> OutperformN/AView Rating Details
7/24/2015Roth CapitalDowngradeBuy -> Sell$5.50 -> $1.00N/AView Rating Details
7/2/2015WedbushReiterated RatingHold$2.00N/AView Rating Details
(Data available from 5/29/2015 forward)

Earnings

Earnings History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Earnings by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Earnings History by Quarter for Sunesis Pharmaceuticals (NASDAQ SNSS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.83)($0.47)$1.57 million$0.67 millionViewListenView Earnings Details
3/9/2017Q4 2016($0.43)($0.44)$0.60 million$0.68 millionViewListenView Earnings Details
11/3/2016Q316($0.71)($0.62)$0.60 million$0.60 millionViewN/AView Earnings Details
7/29/2016Q216($0.10)($0.12)$0.70 million$0.60 millionViewListenView Earnings Details
5/5/2016Q116($0.12)($0.12)$0.77 million$0.64 millionViewListenView Earnings Details
3/10/2016Q415($0.14)($0.15)$0.84 million$0.67 millionViewListenView Earnings Details
11/5/2015Q315($0.12)($0.09)$1.09 million$0.68 millionViewListenView Earnings Details
7/30/2015Q215($0.13)($0.15)$1.21 million$0.85 millionViewN/AView Earnings Details
5/5/2015Q115($0.16)($0.13)$1.14 million$0.90 millionViewListenView Earnings Details
3/12/2015Q414($0.20)($0.02)$1.17 million$0.90 millionViewListenView Earnings Details
11/10/2014Q314($0.17)($0.25)$1.97 million$0.85 millionViewListenView Earnings Details
8/5/2014Q214($0.17)($0.20)$1.32 million$2.00 millionViewListenView Earnings Details
5/7/2014Q114($0.17)($0.26)$1.32 million$2.00 millionViewListenView Earnings Details
3/6/2014Q413($0.20)($0.15)$1.37 million$2.00 millionViewListenView Earnings Details
11/12/2013Q313($0.20)($0.16)$1.44 million$1.99 millionViewListenView Earnings Details
7/29/2013Q2 2013($0.21)$0.18$1.22 million$1.99 millionViewListenView Earnings Details
5/9/2013Q1 2013($0.20)($0.23)$0.75 million$1.99 millionViewListenView Earnings Details
3/13/2013Q4 2012($0.19)($0.20)$0.32 million$1.99 millionViewListenView Earnings Details
11/8/2012Q312($0.11)($0.37)$4.17 million$0.26 millionViewN/AView Earnings Details
8/9/2012($0.20)($0.20)ViewN/AView Earnings Details
5/15/2012($0.18)($0.30)ViewN/AView Earnings Details
11/14/2011($0.18)($0.11)ViewN/AView Earnings Details
8/11/2011($0.15)($0.18)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Current Year EPS Consensus Estimate: $-2.02 EPS
Next Year EPS Consensus Estimate: $-1.60 EPS

Dividends

Dividend History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Insider Ownership Percentage: 14.05%
Institutional Ownership Percentage: 34.30%
Insider Trades by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Institutional Ownership by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Insider Trades by Quarter for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
12/9/2016Geoffrey M ParkerDirectorBuy3,740$3.87$14,473.80View SEC Filing  
5/26/2016Geoffrey M ParkerDirectorBuy9,500$0.47$4,465.00View SEC Filing  
5/25/2016Geoffrey M ParkerDirectorBuy52,505$0.47$24,677.35View SEC Filing  
12/21/2015Dayton MisfeldtDirectorBuy1,750,000$0.84$1,470,000.00View SEC Filing  
8/25/2015Daniel N Swisher JrCEOBuy12,216$1.01$12,338.16View SEC Filing  
8/24/2015Daniel N Swisher JrCEOBuy12,784$1.01$12,911.84View SEC Filing  
8/29/2014Forest BaskettMajor ShareholderSell266,700$7.97$2,125,599.00View SEC Filing  
8/28/2014Bay City Capital LlcMajor ShareholderSell300,700$7.98$2,399,586.00View SEC Filing  
8/28/2014Dayton MisfeldtDirectorSell200,000$7.89$1,578,000.00View SEC Filing  
8/27/2014Adam R CraigCMOSell2,554$8.00$20,432.00View SEC Filing  
8/27/2014Daniel N Swisher JrCEOSell5,000$8.00$40,000.00View SEC Filing  
8/27/2014Dayton MisfeldtDirectorSell100,700$8.16$821,712.00View SEC Filing  
8/27/2014Eric BjerkholtCFOSell10,000$8.00$80,000.00View SEC Filing  
8/27/2014Krishna Kittu KolluriMajor ShareholderSell108,300$8.17$884,811.00View SEC Filing  
8/12/2014Dayton MisfeldtDirectorSell743,700$6.64$4,938,168.00View SEC Filing  
8/12/2014Equity Opportunities Fu GrowthMajor ShareholderSell710,540$6.63$4,710,880.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Latest Headlines for Sunesis Pharmaceuticals (NASDAQ:SNSS)
Source:
DateHeadline
finance.yahoo.com logoIMPORTANT INVESTOR ALERT: Lundin Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm
finance.yahoo.com - May 20 at 5:35 AM
finance.yahoo.com logoThe Life Sciences Report Examines How Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug
finance.yahoo.com - May 19 at 10:01 AM
americanbankingnews.com logo-$0.76 Earnings Per Share Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter
www.americanbankingnews.com - May 15 at 8:16 PM
americanbankingnews.com logoZacks Investment Research Upgrades Sunesis Pharmaceuticals, Inc. (SNSS) to Buy
www.americanbankingnews.com - May 13 at 11:16 PM
finance.yahoo.com logoEdited Transcript of SNSS earnings conference call or presentation 8-May-17 6:00pm GMT
finance.yahoo.com - May 13 at 12:44 AM
americanbankingnews.com logoBrokers Set Expectations for Sunesis Pharmaceuticals, Inc.'s FY2017 Earnings (SNSS)
www.americanbankingnews.com - May 12 at 12:32 PM
finance.yahoo.com logoETFs with exposure to Sunesis Pharmaceuticals, Inc. : May 11, 2017
finance.yahoo.com - May 11 at 9:01 PM
finance.yahoo.com logoSunesis Pharmaceuticals, Inc. :SNSS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 10, 2017
finance.yahoo.com - May 10 at 10:44 AM
globenewswire.com logoSunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights - GlobeNewswire (press release)
globenewswire.com - May 9 at 7:25 PM
americanbankingnews.com logoSunesis Pharmaceuticals, Inc. (SNSS) Releases Quarterly Earnings Results, Beats Expectations By $0.22 EPS
www.americanbankingnews.com - May 8 at 3:18 PM
finance.yahoo.com logoSunesis Pharmaceuticals Reports First Quarter 2017 Financial Results and Recent Highlights
finance.yahoo.com - May 8 at 11:13 AM
finance.yahoo.com logoInvestor Network: Sunesis Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 8 at 11:13 AM
marketbeat.com logoSunesis reports 1Q loss
marketbeat.com - May 8 at 7:06 AM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Khang & Khang LLP Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Encourages Investors with Losses to Contact the Firm
finance.yahoo.com - May 4 at 8:16 PM
businesswire.com logoINVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Sunesis Pharmaceuticals, Inc. Investors
www.businesswire.com - May 3 at 11:07 PM
finance.yahoo.com logoINVESTOR ALERT: Law Offices of Howard G. Smith Commences Investigation on Behalf of Sunesis Pharmaceuticals, Inc. Investors
finance.yahoo.com - May 3 at 11:07 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of Sunesis Pharmaceuticals Inc.
finance.yahoo.com - May 3 at 6:05 PM
finance.yahoo.com logoIMPORTANT SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc. and Advises Investors with Losses to Contact the Firm
finance.yahoo.com - May 3 at 6:05 PM
nasdaq.com logoSunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA)
www.nasdaq.com - May 3 at 10:45 AM
finance.yahoo.com logoSUNESIS INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 Investing In Sunesis Pharmaceuticals Inc. To Contact The Firm
finance.yahoo.com - May 3 at 10:45 AM
finance.yahoo.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Sunesis Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - May 3 at 10:45 AM
finance.yahoo.com logoINVESTOR ALERT: Goldberg Law PC Announces an Investigation of Sunesis Pharmaceuticals, Inc.
finance.yahoo.com - May 3 at 10:45 AM
americanbankingnews.com logoSunesis Pharmaceuticals (SNSS) Earns Media Sentiment Score of -0.05
www.americanbankingnews.com - May 2 at 6:12 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Sunesis Pharmaceuticals, Inc. (SNSS)
finance.yahoo.com - May 2 at 5:46 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sunesis Pharmaceuticals, Inc. - SNSS
finance.yahoo.com - May 2 at 5:46 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Angie's List, Tenet, Chegg, AMD, Coach, Merck, Sunesis Pharma - Nasdaq
www.nasdaq.com - May 2 at 9:21 AM
nasdaq.com logoAZN Gets FDA Nod, CORT Boosts Outlook Yet Again, SNSS Withdraws Vosaroxin MAA - Nasdaq
www.nasdaq.com - May 2 at 9:21 AM
finance.yahoo.com logoSunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin ... - Yahoo Finance
finance.yahoo.com - May 2 at 9:21 AM
streetinsider.com logoSunesis Pharmaceuticals Inc. (SNSS) PT Lowered to $3 at Cantor Fitzgerald Following MAA Withdrawl - StreetInsider.com
www.streetinsider.com - May 2 at 9:21 AM
americanbankingnews.com logoSunesis Pharmaceuticals, Inc. (SNSS) Stock Rating Reaffirmed by Cantor Fitzgerald
www.americanbankingnews.com - May 2 at 8:46 AM
americanbankingnews.com logoSunesis Pharmaceuticals, Inc. (SNSS) Scheduled to Post Quarterly Earnings on Wednesday
www.americanbankingnews.com - May 1 at 7:42 PM
finance.yahoo.com logoSunesis Pharmaceuticals Announces Withdrawal of European Marketing Authorization Application (MAA) for Vosaroxin as a Treatment for Relapsed/Refractory AML
finance.yahoo.com - May 1 at 7:08 PM
finance.yahoo.com logoSunesis shares drop as biotech drops leukemia drug marketing application
finance.yahoo.com - May 1 at 7:08 PM
americanbankingnews.com logoSunesis Pharmaceuticals (SNSS) Getting Favorable Media Coverage, Analysis Finds
www.americanbankingnews.com - April 29 at 7:59 PM
americanbankingnews.com logoZacks: Analysts Anticipate Sunesis Pharmaceuticals, Inc. (SNSS) to Announce -$0.83 EPS
www.americanbankingnews.com - April 25 at 11:33 AM
americanbankingnews.com logoSomewhat Favorable Media Coverage Very Likely to Affect Sunesis Pharmaceuticals (SNSS) Share Price
www.americanbankingnews.com - April 23 at 9:17 PM
americanbankingnews.com logoSunesis Pharmaceuticals (SNSS) Receiving Somewhat Critical Media Coverage, Study Finds
www.americanbankingnews.com - April 17 at 6:35 PM
americanbankingnews.com logoSunesis Pharmaceuticals, Inc. (SNSS) Short Interest Down 4.9% in March
www.americanbankingnews.com - April 16 at 12:20 PM
americanbankingnews.com logoSunesis Pharmaceuticals (SNSS) Getting Positive News Coverage, Report Shows
www.americanbankingnews.com - April 14 at 9:53 PM
streetinsider.com logoSunesis Pharmaceuticals (SNSS) CFO Resigns - StreetInsider.com
www.streetinsider.com - April 14 at 12:29 PM
streetinsider.com logoSunesis Pharmaceuticals (SNSS) CFO Resigns
www.streetinsider.com - April 12 at 8:09 PM
seekingalpha.com logoSunesis Pharmaceuticals (SNSS) Presents At 16th Annual Needham Healthcare Conference - Slideshow
seekingalpha.com - April 7 at 12:41 PM
globenewswire.com logoSunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK ... - GlobeNewswire (press release)
globenewswire.com - April 3 at 8:27 AM
finance.yahoo.com logoSunesis Pharmaceuticals Announces Presentation of The Ohio State University-Sponsored Preclinical Study of BTK Inhibitor SNS-062 at AACR Annual Meeting
finance.yahoo.com - April 3 at 8:27 AM
finance.yahoo.com logoSunesis Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference
finance.yahoo.com - March 28 at 9:17 AM
biz.yahoo.com logoSUNESIS PHARMACEUTICALS INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and E
biz.yahoo.com - March 27 at 7:05 PM
americanbankingnews.com logoFY2017 Earnings Forecast for Sunesis Pharmaceuticals, Inc. (SNSS) Issued By Cantor Fitzgerald
www.americanbankingnews.com - March 23 at 10:17 AM
us.rd.yahoo.com logoSunesis Pharmaceuticals Announces Submission of Responses to the EMA Day 180 List of Outstanding Issues for Marketing Authorization Application for Vosaroxin
us.rd.yahoo.com - March 22 at 8:18 AM
americanbankingnews.com logoZacks Investment Research Lowers Sunesis Pharmaceuticals, Inc. (SNSS) to Hold
www.americanbankingnews.com - March 21 at 8:50 AM
finance.yahoo.com logoSUNESIS PHARMACEUTICALS INC Financials
finance.yahoo.com - March 15 at 8:11 PM

Social

Chart

Sunesis Pharmaceuticals (SNSS) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by MarketBeat.com Staff